Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

57.22 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 243
Open 57.22
Bid (Size) 57.08 (5)
Ask (Size) 57.90 (1)
Prev. Close 57.22
Today's Range 57.22 - 57.22
52wk Range 57.12 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 3.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace

Performance

YTD
-20.81%
-20.81%
1 Month
-5.64%
-5.64%
3 Month
-11.60%
-11.60%
6 Month
-16.96%
-16.96%
1 Year
-18.87%
-18.87%

More News

Read More
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
Via InvestorPlace
Medicare Drug Price Negotiation - What Court's Decision Means for Americans
Via Benzinga
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For September 27
Via Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
2 Undervalued Dividend Stocks to Buy Now
Via The Motley Fool
3 Dividend Stocks to Buy and Hold Until Retirement
Via The Motley Fool
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
Via FinancialNewsMedia
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
From Bristol Myers Squibb
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
Via InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Via Talk Markets
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
Via Benzinga
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Via InvestorPlace
Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth
Via Benzinga
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
From Bristol Myers Squibb
Via Business Wire
The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.
Via InvestorPlace
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.